Edition:
United States

Vexim SA (ALVXM.PA)

ALVXM.PA on Paris Stock Exchange

15.65EUR
--
Change (% chg)

-- (--)
Prev Close
€15.65
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
8,318
52-wk High
€17.50
52-wk Low
€8.92

Select another date:

Thu, Sep 14 2017

BRIEF-Vexim H1 net operating loss narrows to 1.5 million euros

* VEXIM: STRONG FIRST HALF 2017 RESULTS, IN LINE WITH EXPECTATIONS

BRIEF-Vexim Q2 sales rise to 5.7 million euros

* ANTICIPATES A CONTINUED STRONG GROWTH IN SALES IN SECOND PART OF 2017 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Vexim says Anvisa approves Spinejack implants in Brazil

* HAS RECEIVED REGULATORY APPROVAL FROM ANVISA(1), BRAZIL'S NATIONAL HEALTH SURVEILLANCE AGENCY, IN ORDER TO COMMERCIALIZE SPINEJACK® IN BRAZIL.

BRIEF-Vexim aims at reaching profitability on full year basis in 2017

* AIMS AT REACHING PROFITABILITY ON FULL YEAR BASIS IN 2017 AND FUTURE CASH FLOWS SHOULD ALLOW VEXIM TO SELF-FINANCE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Vexim: in Q1, 19 pct growth of sales at 4.7 million euros

* Continued growth and adoption of SpineJack in Q1 2017: +19 pct growth of sales at 4.7 million euros ($5.0 million)

BRIEF-Vexim launches Masterflow plus in Germany

* New product launch in Germany: Masterflow plus, a new product targeted at low energy osteoporotic fractures Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

Select another date: